Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecular Subtyping Based on Specific HLA-I Genotypes for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma: A Retrospective Observational Cohort Study

NCT05483257 is registered in ClinicalTrials.gov with BAIYONG SHEN as lead sponsor.

NCT NCT05483257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05483257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecular Subtyping Based on Specific HLA-I Genotypes for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma: A Retrospective Observational Cohort Study
Lead sponsor
BAIYONG SHEN
Phase
Observational
Overall status
Completed
Start date
March 14, 2018
Completion date
September 13, 2021
Enrollment
226 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer resectable